| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Xenon Pharmaceuticals Inc. (XENE) has 5 insiders with recent SEC Form 4 filings, including 14 buys and 1 sell. XENE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 30.0K | $1.64M | - | |
| Other | 20.0K | $1.10M | - | |
| CEO | 19.9K | $1.09M | - | |
| Other | 7.3K | $400.0K | - | |
| Other | 7.1K | $387.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2019 | Azab Mohammad | Director | Sell | 23 | $9.31 | $214.18 | - | |
| Nov 15, 2017 | Azab Mohammad | Director | Buy | 15,000 | $2.22 | $33,280.50 | +51.4% | |
| Sep 22, 2017 | Azab Mohammad | Director | Buy | 10,000 | $2.95 | $29,500.00 | +24.7% | |
| Aug 18, 2017 | Winquist Raymond | Head, Translational Research | Buy | 1,000 | $3.00 | $2,995.00 | New | |
| Aug 18, 2017 | Azab Mohammad | Director | Buy | 6,335 | $2.90 | $18,362.59 | +24.6% | |
| Aug 15, 2017 | Empfield James R.47 | SVP, Drug Discovery | Buy | 10,000 | $2.48 | $24,824.00 | New | |
| Aug 15, 2017 | Bvf Partners L P/il59 | 10% Owner | Buy | 60,202 | $2.61 | $157,266.91 | +1.1% | |
| Aug 14, 2017 | Hayden Michael R58 | Director | Buy | 15,000 | $2.75 | $41,247.00 | +10.3% | |
| Aug 14, 2017 | Svoronos Dawn | Director | Buy | 50,000 | $2.82 | $140,770.00 | New | |
| Aug 11, 2017 | Gannon Steven | Director | Buy | 15,000 | $2.82 | $42,267.00 | New |